Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 103


Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.

Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, Ndashimye E, Kityo CM, Salata RA, Mugyenyi P, Arts EJ, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16. Print 2016 Jun.


HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Tebit DM, Patel H, Ratcliff A, Alessandri E, Liu J, Carpenter C, Plantier JC, Arts EJ.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):676-88. doi: 10.1089/AID.2015.0318. Epub 2016 Mar 16.


Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage.

Nankya IL, Tebit DM, Abraha A, Kyeyune F, Gibson R, Jegede O, Nickel G, Arts EJ.

AIDS Res Ther. 2015 Oct 3;12:34. doi: 10.1186/s12981-015-0066-7. eCollection 2015.


Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants.

Bagaya BS, Vega JF, Tian M, Nickel GC, Li Y, Krebs KC, Arts EJ, Gao Y.

Retrovirology. 2015 May 23;12:44. doi: 10.1186/s12977-015-0170-8.


SiRNA-induced mutation in HIV-1 polypurine tract region and its influence on viral fitness.

Rausch JW, Tian M, Li Y, Angelova L, Bagaya BS, Krebs KC, Qian F, Zhu C, Arts EJ, Le Grice SF, Gao Y.

PLoS One. 2015 Apr 10;10(4):e0122953. doi: 10.1371/journal.pone.0122953. eCollection 2015.


Similar replicative fitness is shared by the subtype B and unique BF recombinant HIV-1 isolates that dominate the epidemic in Argentina.

Rubio AE, Abraha A, Carpenter CA, Troyer RM, Reyes-Rodríguez ÁL, Salomon H, Arts EJ, Tebit DM.

PLoS One. 2014 Apr 11;9(4):e92084. doi: 10.1371/journal.pone.0092084. eCollection 2014.


Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds.

Liu Y, Rao U, McClure J, Konopa P, Manocheewa S, Kim M, Chen L, Troyer RM, Tebit DM, Holte S, Arts EJ, Mullins JI.

PLoS One. 2014 Apr 8;9(4):e94240. doi: 10.1371/journal.pone.0094240. eCollection 2014.


Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women.

Lemonovich TL, Watkins RR, Morrison CS, Kwok C, Chipato T, Musoke R, Arts EJ, Nankya I, Salata RA.

J Int Assoc Provid AIDS Care. 2015 Sep-Oct;14(5):415-22. doi: 10.1177/2325957413504827. Epub 2013 Oct 8.


Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Lobritz MA, Ratcliff AN, Marozsan AJ, Dudley DM, Tilton JC, Arts EJ.

Antimicrob Agents Chemother. 2013 Jun;57(6):2640-50. doi: 10.1128/AAC.02511-12. Epub 2013 Mar 25.


Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.

Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, Rose JD, Wylie D, Henry K, Wright A, King K, Archer J, Poveda E, Soriano V, Robertson DL, Olivo PD, Arts EJ, Quiñones-Mateu ME.

J Clin Microbiol. 2013 May;51(5):1517-27. doi: 10.1128/JCM.00092-13. Epub 2013 Mar 13.


A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation.

Chamanian M, Purzycka KJ, Wille PT, Ha JS, McDonald D, Gao Y, Le Grice SF, Arts EJ.

Cell Host Microbe. 2013 Feb 13;13(2):181-92. doi: 10.1016/j.chom.2013.01.007.


Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.

Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quiñones-Mateu ME.

PLoS One. 2012;7(11):e49602. doi: 10.1371/journal.pone.0049602. Epub 2012 Nov 14.


Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus.

King DF, Siddiqui AA, Buffa V, Fischetti L, Gao Y, Stieh D, McKay PF, Rogers P, Ochsenbauer C, Kappes JC, Arts EJ, Shattock RJ.

J Virol. 2013 Jan;87(2):890-9. doi: 10.1128/JVI.02216-12. Epub 2012 Nov 7.


HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Ratcliff AN, Shi W, Arts EJ.

J Virol. 2013 Jan;87(2):923-34. doi: 10.1128/JVI.01863-12. Epub 2012 Nov 7.


A hybrid stochastic-deterministic computational model accurately describes spatial dynamics and virus diffusion in HIV-1 growth competition assay.

Immonen T, Gibson R, Leitner T, Miller MA, Arts EJ, Somersalo E, Calvetti D.

J Theor Biol. 2012 Nov 7;312:120-32. doi: 10.1016/j.jtbi.2012.07.005. Epub 2012 Jul 17.


HIV-1 antiretroviral drug therapy.

Arts EJ, Hazuda DJ.

Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161. doi: 10.1101/cshperspect.a007161. Review.


Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Santos AF, Tebit DM, Lalonde MS, Abecasis AB, Ratcliff A, Camacho RJ, Diaz RS, Herchenröder O, Soares MA, Arts EJ.

Antimicrob Agents Chemother. 2012 May;56(5):2719-25. doi: 10.1128/AAC.06079-11. Epub 2012 Feb 13.


Past, present, and future of entry inhibitors as HIV microbicides.

Gibson RM, Arts EJ.

Curr HIV Res. 2012 Jan 1;10(1):19-26. Review.


Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, Rhea AM, Henry K, Pappas J, Wright A, Mohamed N, Gibson R, Rodriguez B, Soriano V, King K, Arts EJ, Olivo PD, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2011 Aug;55(8):3729-42. doi: 10.1128/AAC.00396-11. Epub 2011 May 31.

Items per page

Supplemental Content

Write to the Help Desk